1.	Phase II Study of Dolastatin 10 in Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: VCC-9802, NCI-T98-0007, NCT00005579, T98-0007
2.	Phase II Study of Dolastatin 10 in Patients with Unresectable or Metastatic Adenocarcinoma of the Colon or Rectum (Summary Last Modified 03/2000) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-DM-98062, NCI-T98-0018, T98-0018
3.	Phase II Study of Dolastatin 10 in Patients with Previously Treated Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-983251, NCCTG-98-32-51
4.	Phase II Study of Dolastatin 10 in Patients with Locally Advanced, Unresectable, or Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CHNMC-IRB-98039, NCI-T98-0009, T98-0009
5.	Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000066620, UCCRC-9409, NCI-T98-0010, T98-0010, NCT00003557
6.	Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: CDR0000066708, WSU-D-1644, NCI-T98-0019, T98-0019, NCT00003626
7.	Phase II Study of Dolastatin 10 in Patients With Advanced Non-Small Cell Lung Cancer (Summary Last Modified 10/1999) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-98070, NCI-T98-0016, T98-0016
8.	Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: DM98-071, P30CA016672, U01CA070172, U01CA063187, MDA-DM-98071, NCI-T98-0028, CDR0000066778, T98-0028, NCT00003677
9.	Phase II Study of Dolastatin 10 in Patients With Recurrent or Metastatic Soft Tissue Sarcoma (Summary Last Modified 09/2000) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: FCCC-98019, NCI-T98-0026, NCT00003778
10.	Phase II Study of Dolastatin 10 in Patients With Recurrent or Metastatic, Platinum Sensitive Ovarian Epithelial Cancer or Primary Peritoneal Cancer Phase: Phase II Type: Treatment Status: Completed Age: Any age Sponsor: NCI Protocol IDs: GOG-146J
11.	Dolastatin 10 in Treating Patients With Advanced Kidney Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067094, P30CA015083, 975002, T98-0024, 372-99, MAYO-975002, NCI-T98-0024, NCT00003914
12.	Phase I Study of Dolastatin 10 for Advanced Solid Tumors (Summary Last Modified 04/2000) Phase: Phase I Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-DM-95045, NCI-T95-0018D, T95-0018
13.	Phase I Study of Dolastatin-10 for Advanced Malignancies (Summary Last Modified 04/98) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-940102, NCI-T95-0007H, T95-0007
14.	Phase I Study of Dolastatin 10 in Children with Refractory Solid Tumors (Summary Last Modified 01/2001) Phase: Phase I Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: CCG-09718
15.	Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Phase: Phase I Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: DM98-187, U01CA062461, P30CA016672, MDA-DM-98187, NCI-T98-0001, CDR0000066796, T98-0001, NCT00003693